ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LIFE aTyr Pharma Inc

1.94
-0.06 (-3.00%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 726,167
Bid Price 1.92
Ask Price 1.97
News -
Day High 2.05

Low
1.0801

52 Week Range

High
2.6999

Day Low 1.8901
Company Name Stock Ticker Symbol Market Type
aTyr Pharma Inc LIFE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -3.00% 1.94 17:05:12
Open Price Low Price High Price Close Price Prev Close
2.04 1.8901 2.05 1.95 2.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,378 726,167 $ 1.96 $ 1,425,833 - 1.0801 - 2.6999
Last Trade Time Type Quantity Stock Price Currency
18:55:43 10 $ 1.9694 USD

aTyr Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
132.11M 67.75M - 10.39M -45.34M -0.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

aTyr Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LIFE Message Board. Create One! See More Posts on LIFE Message Board See More Message Board Posts

Historical LIFE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.002.091.851.98613,234-0.06-3.00%
1 Month1.902.151.551.83675,5800.042.11%
3 Months1.602.151.3951.82548,7850.3421.25%
6 Months1.632.151.08011.62419,3680.3119.02%
1 Year1.952.69991.08011.87446,506-0.01-0.51%
3 Years4.5813.101.08017.06712,203-2.64-57.64%
5 Years7.2813.101.08016.58585,332-5.34-73.35%

aTyr Pharma Description

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

Your Recent History

Delayed Upgrade Clock